Home › NDC Lookup › RxCUI directory › RxCUI 1989823

5 ML vestronidase alfa-vjbk 2 MG/ML Injection — RxCUI 1989823

RxNorm drug concept · Semantic clinical drug
RxCUI 1989823 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1989823
Official name5 ML vestronidase alfa-vjbk 2 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asvestronidase alfa-vjbk 10 MG per 5 ML Injection; vestronidase alfa-vjbk 10 MG in 5 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)40 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 5 ML vestronidase alfa-vjbk 2 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 5 ML vestronidase alfa-vjbk 2 MG/ML Injection RxCUI 1989823

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Vestronidase alfa 1989819
    • Vestronidase alfa-vjbk 1989818
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mepsevii 1989824
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Vestronidase alfa Injection 1989822
    • Vestronidase alfa-vjbk Injection 2645531
    • Vestronidase alfa Injectable Product 1989821
    • Vestronidase alfa-vjbk Injectable Product 2662863
    • Vestronidase alfa Injection [Mepsevii] 1989826
    • Vestronidase alfa-vjbk Injection [Mepsevii] 2655551
    • Mepsevii Injectable Product 1989827
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Vestronidase alfa-vjbk 2 MG/ML SCDC · 1989820
  • Vestronidase alfa Injection SCDF · 1989822
  • Vestronidase alfa-vjbk Injection SCDFP · 2645531
  • Vestronidase alfa Injectable Product SCDG · 1989821
  • Vestronidase alfa-vjbk Injectable Product SCDGP · 2662863

Brand-Name Concepts

  • 5 ML vestronidase alfa-vjbk 2 MG/ML Injection [Mepsevii] SBD · 1989828
  • Vestronidase alfa-vjbk 2 MG/ML [Mepsevii] SBDC · 1989825
  • Vestronidase alfa Injection [Mepsevii] SBDF · 1989826
  • Vestronidase alfa-vjbk Injection [Mepsevii] SBDFP · 2655551
  • Mepsevii Injectable Product SBDG · 1989827
  • Mepsevii BN · 1989824

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1989823 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69794-0001-01 1 VIAL, SINGLE-USE in 1 CARTON (69794-001-01) / 5 mL in 1 V... MEPSEVII Ultragenyx Pharmaceutical Inc. 2017-11-15
Observed labelers: Ultragenyx Pharmaceutical Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.